뇌내 희돌기교종의 방사선치료 성적 및 예후인자

The Efficiency of Radiation Therapy in the Treatment of Intracranial Oligodendrogliomas : Factors Influencing the Prognosis

  • 윤세철 (가톨릭대학교 강남성모병원 치료방사선과, 암센타) ;
  • 계철승 (가톨릭대학교 강남성모병원 치료방사선과, 암센타) ;
  • 정수미 (가톨릭대학교 강남성모병원 치료방사선과, 암센타) ;
  • 유미령 (가톨릭대학교 강남성모병원 치료방사선과, 암센타) ;
  • 김연실 (가톨릭대학교 강남성모병원 치료방사선과, 암센타) ;
  • 홍용길 (가톨릭대학교 강남성모병원 신경외과, 암센타) ;
  • 김문찬 (가톨릭대학교 강남성모병원 신경외과, 암센타) ;
  • 강준기 (가톨릭대학교 강남성모병원 신경외과, 암센타)
  • Yoon Sei Chul (Department of Radiation Oncology, Catholic Cancer Center, Catholic University of Korea) ;
  • Kay Chul Seung (Department of Radiation Oncology, Catholic Cancer Center, Catholic University of Korea) ;
  • Chung Su Mi (Department of Radiation Oncology, Catholic Cancer Center, Catholic University of Korea) ;
  • Ryu Mi Ryung (Department of Radiation Oncology, Catholic Cancer Center, Catholic University of Korea) ;
  • Kim Yeon Shil (Department of Radiation Oncology, Catholic Cancer Center, Catholic University of Korea) ;
  • Hong Yong Kil (Department of Neurosurgery, Kangnam St. Mary's Hospital, Catholic Cancer Center, Catholic University of Korea) ;
  • Kim Moon Chan (Department of Neurosurgery, Kangnam St. Mary's Hospital, Catholic Cancer Center, Catholic University of Korea) ;
  • Kang Joon Ki (Department of Neurosurgery, Kangnam St. Mary's Hospital, Catholic Cancer Center, Catholic University of Korea)
  • 발행 : 2002.09.01

초록

목적 : 희돌기교종은 천천히 자라는 낮은 빈도의 뇌 종양으로서 수술로 치유되지만 완전절제가 어려워 수술후 방사선치료가 추천되고 있다. 희돌기교종 환자의 방사선치료후 생존율과 이 생존율에 영향을 미치는 예후 인자들을 알아보기 위해 이 연구를 하였다. 대상 및 방법 : 1983년 3월 부터 1997년 12월 까지 177개월 동안에 가톨릭대학교 강남성모병원 치료방사선과에서는 조직학적 진단이 확진된 총 42예(남:여 = 25:17)의 희돌기교종 환자에 대한 방사선치료를 실시하였다. 방사선치료는 6 MV 선형가속기를 이용하여 180 cGy/일, 주 5회 씩, 총 조사선량 $39.6\~75.6\;Gy$ (중앙값 54 Gy)를 실시하였다. 환자의 나이는 $5\~62$세(중앙값 39세)에 분포하였으며 추적조사 기간은 $8\~152$개월(평균 63.4개월)이었다. 방사선치료 종료일을 기준으로 생존율(Kaplan-Meier 법)과 이 생존율에 영향을 미치는 인자들을 후향적으로 분석하였다. 결과 : 방사선치료후 5년 생존율(5YSR)은 $65.3\%$ 이었다(중앙값 90개월). 종양의 수술적 제거를 실시한 경우가 조직 생검 만을 한 경우 보다 생존율이 좋았으며$(5YSR;\;69.9\%\;vs\;26.7\%;\;p<0.01)$, 수술후 방사선치료를 4주 이내에 실시한 군이 4주 이후의 경우보다 생존율이 좋은 것으로 나타났다$(5YSR;\;86\%\;vs\;49\%;\;p<0.03)$. 종양에 대한 방사선 총 조사선량이 60 Gy 이상인 군에서는 60 Gy 이하 치료한 군에 비하여 생존율의 증가를 보이지 않았다$(5YSR;\;74.9\%\;vs\;33.3\%;\;p<0.02)$. 조직학적 악성 분화도가 높을수록 생존율은 낮았으며(p<0.01). 종양의 크기, 뇌내 종양의 위치, 전뇌 방사선조사의 유무, 방사선치료에 소요된 총 기간, 성별, 나이, 화학요법 치료 유무 등에 따른 생존율 변화의 차이는 없는 것으로 분석되었다(p>0.05). 결론 : 희돌기교종 환자의 방사선치료는 국소적으로 병소부위에 수술후 4주 이내에 실시하여 생존율 증가를 관찰 할 수 있었다. 또한 전통적인 분할 방사선치료 시 총 방사선조사선량이 60 Gy 이상은 생존율을 증가시키지 못하였다.

Purpose : Oligodendrogliomas (ODG) are a rare, slow growing, tumor in the brain, which can be cured by complete surgical resection, but as yet it is not known if postoperative adjuvant radiation therapy (RT) is essential, We analyzed the treatment results of patients with irradiated ODG to investigate the efficacy of RT in terms of survival rates and other influencing prognostic factors. Methods and Materials : Between March 1983 and December 1997, 42 patients with ODG were treated with RT at our hospital. The RT was peformed dally at a dose of $1.8\~2.0\;Gy$, at 5 fractions per week, to a total dose of between 39.6 Gy and 64.8 Gy (mean 53.3 Gy). The ages of the patients ranged between 5 and 62 years, with a median age of 39 years. The mean follow-up period was 63.4 months (8-152 months). The Kaplan-Meier method was used to assess the survival, and 5 year survival rates (5-YSR). Log rank tests and Cox regression analyses were used to define the significance of prognostic factors. Results : The majority of ODG in this study were located in the cerebral hemisphere $(83.3\%)$. ODG are slightly more common in men than women, and commonly occurs in middle age, between the 3rd and 4th decades. It has been recommended that RT is commenced within 4 weeks following surgery (5-YSR; $86\%\;vs.\;49\%;\;p<0.03$). Histologically well differentiated, as opposed to poorly differentiated, tumors were found to have a more favorable prognosis (p<0.02). The actuarial 5-YSR was $65.3\%$ (median survival 90 months). 5-YSR for the various extents of surgical excision, followed by external RT, was superior to that of biopsy only followed by external RT $(69.9\%\;vs.\;25.6\%,\;p<0.01)$. Tumor size and location, overall elapsed irradiation days, age, sex, whole brain irradiation as a course of treatment and chemotherapy, had no influence on the 5-YSR (p>0.05). Conclusion : A local involved field irradiation with conventional fractionation, commencing within 4 weeks following surgical excision of the tumor, was beneficial for the 5-YSR, but a total radiation dose exceeding 60 Gy did not improve the 5-YSR.

키워드

참고문헌

  1. Mork SJ, Lindergaard KF, Halvonsen TB et al. Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 1985:63:881-889
  2. Macdonard DR. Low-grade gliomas, mixed gliomas and oligodendrogliomas. Semin Oncol 1994:21:236-248
  3. Sun ZM, Genka S, Shitara N et al. Factors possibly influencing the prognosis of oligodendroglioma. Neurosurgery 1988;22:886-891 https://doi.org/10.1227/00006123-198805000-00015
  4. Gannett DE, Wisbeck WM, Silbergeld DL et al. The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 1994:30:567-573
  5. Smith MT, Ludwig CL, Godfrey AD et al. Grading of oligodendrogliomas. Cancer 1983;52:2107-2114 https://doi.org/10.1002/1097-0142(19831201)52:11<2107::AID-CNCR2820521123>3.0.CO;2-X
  6. Sheline GE, Boldrey E, Karlsberg P et al. Therapeutic considerations in tumors affecting the central nervous system: Oligodendrogliomas. Radiology 1964:82:84-89
  7. Shenkin HA. The effect of roentogen-ray therapy on oligodendrogliomas of the brain. J Neurosurg 1965;22:57-59 https://doi.org/10.3171/jns.1965.22.1.0057
  8. Hirsch JF, Rose CS, Kahn AP et al. Benign astrocytic and oligodendrocytic tumors of the cerebral hemispheres in children. J Neurosurg 1989;70:568-572 https://doi.org/10.3171/jns.1989.70.4.0568
  9. Reedy DP, Bay JW, Hahn JF. Role of radiation therapy in the treatment of cerebral oligodendroglioma: An analysis of 57 cases and literature review. Neurosurgery 1983;13:499-503 https://doi.org/10.1227/00006123-198311000-00003
  10. Bullard DE, Rawlings CE III, Philips B et al. Oligodendroglioma. An analysis of the values of radiation therapy. Cancer 1987;60:2179-2188 https://doi.org/10.1002/1097-0142(19871101)60:9<2179::AID-CNCR2820600912>3.0.CO;2-G
  11. Shaw EG, Scheithauer BW, O'Fallow JR et al. Oligodendrogliomas : the Mayo Clinic experience. J Neurosurgery 1992;76:428-434 https://doi.org/10.3171/jns.1992.76.3.0428
  12. Burger PC, Rawlings CE, Cox EB et al. Clinicopathologic correlations in the oligodendroglioma. Cancer 1987;59:1345-1352 https://doi.org/10.1002/1097-0142(19870401)59:7<1345::AID-CNCR2820590719>3.0.CO;2-A
  13. Wallner KE, Gonzales M, Sheline G. Treatment of oligodendrogliomas with or without irradiation. J Neurosurgery 1988;68:684-688 https://doi.org/10.3171/jns.1988.68.5.0684
  14. Chin HW, Hazel JJ, Kim TH et al. Oligodendrogliomas I : A clinical study of cerebral oligodendroglioma. Cancer 1980;45:1458-1466 https://doi.org/10.1002/1097-0142(19800315)45:6<1458::AID-CNCR2820450627>3.0.CO;2-0
  15. Leibel SA. Primary and metastatic brain tumors in adults. In: Leibel SA, Phillip TL, eds. Textbook of Radiation Oncology. 1st ed. Philadelphia, WB Saunders Co. 1998:306-309
  16. Couldwell WT, Hinton DR. Oligodendroglioma. In: Kaye AH, Laws ER eds. Brain Tumors 1st ed. New York, Churchill Livingstone, 1995:479-490
  17. Yoon SC, Kim SW, Chung SM et al. The effect of radiation therapy on oligodendrogliomas. J Korean Soc Ther Radiol 1991;9:47-52
  18. Reichenthal E, Feldman Z, Cohen ML, et al. Hemispheric supratentorial low grade astrocytoma. Neurochirurgia 1992;35:18-22
  19. Shaw EG, Daumas-Duport C, Scheithauer BW et al. Radiation therapy in the management of low grade supratentorial astrocytomas. J Neurosurgery 1989;70:853-861 https://doi.org/10.3171/jns.1989.70.6.0853
  20. Medbery CA III, Straus KL, Steinberg SM et al. Low grade astrocytoma: Treatment results and prognostic variables. Int J Rad Oncol Biol Phys 1988;15:837-841 https://doi.org/10.1016/0360-3016(88)90115-0
  21. North CA, North RB, Epstein JA et al. Low grade cerebral astrocytoma: Survival and quality of life after radiation therapy. Cancer 1990;66:6-14 https://doi.org/10.1002/1097-0142(19900701)66:1<6::AID-CNCR2820660103>3.0.CO;2-F
  22. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988;23:360-364 https://doi.org/10.1002/ana.410230408
  23. Henderson KH, Shaw EG. Randomized trials of radation therapy inadult low-grade gliomas. Seminars in Radation Oncology 2001;11:145-151 https://doi.org/10.1053/srao.2001.21424